Cargando…

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study

BACKGROUND: Circulating tumor cell (CTC) count have prognostic role for metastatic breast cancer (MBC). No clear biomarkers can guide selection of chemotherapy (CT) or endocrine therapy (ET) in 1st-line setting of hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR(+)...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Bin, Li, Huiping, Zhang, Jiayang, Liu, Xiaoran, Song, Guohong, Jiang, Hanfang, Yan, Ying, Wang, Huan, Wang, Jing, Di, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469166/
https://www.ncbi.nlm.nih.gov/pubmed/36111005
http://dx.doi.org/10.21037/atm-22-3797
_version_ 1784788580724375552
author Shao, Bin
Li, Huiping
Zhang, Jiayang
Liu, Xiaoran
Song, Guohong
Jiang, Hanfang
Yan, Ying
Wang, Huan
Wang, Jing
Di, Lijun
author_facet Shao, Bin
Li, Huiping
Zhang, Jiayang
Liu, Xiaoran
Song, Guohong
Jiang, Hanfang
Yan, Ying
Wang, Huan
Wang, Jing
Di, Lijun
author_sort Shao, Bin
collection PubMed
description BACKGROUND: Circulating tumor cell (CTC) count have prognostic role for metastatic breast cancer (MBC). No clear biomarkers can guide selection of chemotherapy (CT) or endocrine therapy (ET) in 1st-line setting of hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR(+)HER2(−)) MBC. The present study investigated the prognostic role CT or ET according to the CTC count in HR(+)HER2(−) MBC. METHODS: We consecutively collected the data of 53 HR(+)HER2(−) MBC patients who received 1st-line CT or ET, who had CTC count detected by our peptide-based nanomagnetic CTC isolation system (Pep@MNPs) from January 2014 to December 2015. The clinicopathological characteristics according the CTC count and 1st-line ET vs. CT were compared. Follow-up was conducted every 6 months. The primary endpoint was progression-free survival (PFS) and overall survival (OS). A Cox regression analysis was conducted to determine the prognostic roles of CTC and 1st-line therapy of ET vs. CT for PFS and OS. RESULTS: The median CTC count of the 53 patients was 2 (range, 0–18). The clinicopathological characteristics of the patients in the CTC count <2 group and the CTC count ≥2 group were similar. The patients with a CTC count <2 had a significantly longer PFS than those with a CTC count ≥2 (P=0.005, hazard ratio =4.138, 12.1 vs. 7.1 months). The patients who received CT had a significantly longer PFS than those who received ET (P=0.041, hazard ratio =2.721, 9.9 vs. 7.2 months). In the CTC count ≥2 group, the patients who received CT had a significantly longer PFS than those who received ET (P=0.048, hazard ratio =2.475, 8.7 vs. 6.3 months). In the CTC count <2 group, there was no significant difference in PFS between the CT and ET groups (P=0.071). Additionally, the CTC count had no significant effect on OS (P=0.116, hazard ratio =2.391, 54.2 vs. 34.2 months). CONCLUSIONS: The present study showed that CTC count determined by the Pep@MNP system confirmed the prognostic value in the HR(+)HER2(−) MBC patients. And it might be helpful in choosing a 1st-line treatment of CT or ET for HR(+)HER2(−) MBC patients.
format Online
Article
Text
id pubmed-9469166
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-94691662022-09-14 The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study Shao, Bin Li, Huiping Zhang, Jiayang Liu, Xiaoran Song, Guohong Jiang, Hanfang Yan, Ying Wang, Huan Wang, Jing Di, Lijun Ann Transl Med Original Article BACKGROUND: Circulating tumor cell (CTC) count have prognostic role for metastatic breast cancer (MBC). No clear biomarkers can guide selection of chemotherapy (CT) or endocrine therapy (ET) in 1st-line setting of hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR(+)HER2(−)) MBC. The present study investigated the prognostic role CT or ET according to the CTC count in HR(+)HER2(−) MBC. METHODS: We consecutively collected the data of 53 HR(+)HER2(−) MBC patients who received 1st-line CT or ET, who had CTC count detected by our peptide-based nanomagnetic CTC isolation system (Pep@MNPs) from January 2014 to December 2015. The clinicopathological characteristics according the CTC count and 1st-line ET vs. CT were compared. Follow-up was conducted every 6 months. The primary endpoint was progression-free survival (PFS) and overall survival (OS). A Cox regression analysis was conducted to determine the prognostic roles of CTC and 1st-line therapy of ET vs. CT for PFS and OS. RESULTS: The median CTC count of the 53 patients was 2 (range, 0–18). The clinicopathological characteristics of the patients in the CTC count <2 group and the CTC count ≥2 group were similar. The patients with a CTC count <2 had a significantly longer PFS than those with a CTC count ≥2 (P=0.005, hazard ratio =4.138, 12.1 vs. 7.1 months). The patients who received CT had a significantly longer PFS than those who received ET (P=0.041, hazard ratio =2.721, 9.9 vs. 7.2 months). In the CTC count ≥2 group, the patients who received CT had a significantly longer PFS than those who received ET (P=0.048, hazard ratio =2.475, 8.7 vs. 6.3 months). In the CTC count <2 group, there was no significant difference in PFS between the CT and ET groups (P=0.071). Additionally, the CTC count had no significant effect on OS (P=0.116, hazard ratio =2.391, 54.2 vs. 34.2 months). CONCLUSIONS: The present study showed that CTC count determined by the Pep@MNP system confirmed the prognostic value in the HR(+)HER2(−) MBC patients. And it might be helpful in choosing a 1st-line treatment of CT or ET for HR(+)HER2(−) MBC patients. AME Publishing Company 2022-08 /pmc/articles/PMC9469166/ /pubmed/36111005 http://dx.doi.org/10.21037/atm-22-3797 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Shao, Bin
Li, Huiping
Zhang, Jiayang
Liu, Xiaoran
Song, Guohong
Jiang, Hanfang
Yan, Ying
Wang, Huan
Wang, Jing
Di, Lijun
The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
title The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
title_full The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
title_fullStr The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
title_full_unstemmed The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
title_short The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
title_sort prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in hr(+)her2(−) metastatic breast cancer: a retrospective study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469166/
https://www.ncbi.nlm.nih.gov/pubmed/36111005
http://dx.doi.org/10.21037/atm-22-3797
work_keys_str_mv AT shaobin theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT lihuiping theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT zhangjiayang theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT liuxiaoran theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT songguohong theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT jianghanfang theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT yanying theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT wanghuan theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT wangjing theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT dilijun theprognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT shaobin prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT lihuiping prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT zhangjiayang prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT liuxiaoran prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT songguohong prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT jianghanfang prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT yanying prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT wanghuan prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT wangjing prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy
AT dilijun prognosticvalueofchemotherapyorendocrinetherapychoiceaccordingtocirculatingtumorcellcountinhrher2metastaticbreastcanceraretrospectivestudy